Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status (CENTRIC) - Estimated Completion June 2016
  • PDF

Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status (CENTRIC) - Estimated Completion June 2016

  • Saturday, 22 January 2011 07:45

Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status (CENTRIC)
This study is currently recruiting participants.
Verified by EMD Serono, May 2010
First Received: May 29, 2008   Last Updated: May 24, 2010   History of Changes
Sponsor: EMD Serono
Collaborator: European Organization for Research and Treatment of Cancer
Information provided by: EMD Serono
ClinicalTrials.gov Identifier: NCT00689221
Purpose

CENTRIC is a Phase III clinical trial assessing efficacy and safety of the investigational integrin inhibitor, cilengitide, in combination with standard treatment versus standard treatment alone in newly diagnosed Glioblastoma Multiforme (GBM) patients with a methylated promoter of the methylguanine-DNA methyltransferase (MGMT) gene in the Tumor tissue.

The MGMT gene promoter is a section of DNA that acts as a controlling element in the expression of MGMT. Methylation of the MGMT gene promoter has been found to be a predictive marker for benefit from temozolomide (TMZ) treatment.


Condition Intervention Phase
Glioblastoma
Drug: Cilengitide, Temozolomide & Radiotherapy
Drug: Temozolomide & Radiotherapy
Phase III

Study Type: Interventional
Study Design: Allocation: Randomized
Control: Active Control
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Cilengitide for Subjects With Newly Diagnosed Glioblastoma Multiforme and Methylated MGMT Gene Promoter - A Multicenter, Open-label, Controlled Phase III Study, Testing Cilengitide in Combination With Standard Treatment (Temozolomide With Concomitant Radiation Therapy, Followed by Temozolomide Maintenance Therapy) Versus Standard Treatment Alone

Resource links provided by NLM:


Further study details as provided by EMD Serono:

Primary Outcome Measures:
  • Overall Survival [ Time Frame: various timepoints ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Safety and tolerability, PFS, QoL and population PK [ Time Frame: various timepoints ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 504
Study Start Date: September 2008
Estimated Study Completion Date: June 2016
Estimated Primary Completion Date: September 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
1: Experimental
Cilengitide, Radiotherapy & Temozolomide
Intervention: Drug: Cilengitide, Temozolomide & Radiotherapy
Drug: Cilengitide, Temozolomide & Radiotherapy
Cilengitide 2000mg i.v. twice weekly, Temozolomide & Radiotherapy
2
Temozolomide & Radiotherapy
Intervention: Drug: Temozolomide & Radiotherapy
Drug: Temozolomide & Radiotherapy
Temozolomide & Radiotherapy

Eligibility

Ages Eligible for Study: 18 Years and older
Genders Eligible for Study: Both
Accepts Healthy Volunteers: No
Criteria

Inclusion Criteria:

  1. Tumor tissue specimens from the GBM surgery or open biopsy (formalin-fixed, paraffin-embedded block; stereotactic biopsy not allowed) must be available for MGMT status analysis and central pathology review.
  2. Newly diagnosed histologically proven supratentorial GBM (World Health Organization [WHO] Grade IV).
  3. Proven methylated MGMT gene promoter methylation status.
  4. Available post-operative Gd- MRI performed within <48 hours after surgery (in case it was not possible to obtain a Gd-MRI within <48 hours post surgery, a Gd-MRI is to be performed prior to randomization).
  5. Stable or decreasing dose of steroids for ³5 days prior to randomization
  6. ECOG PS of 0-1.
  7. Meets 1 of the following RPA classifications:• Class III (Age <50 years and ECOG PS 0). Class IV (meeting one of the following criteria: a) Age <50 years and ECOG PS 1 or b) Age ≥50 years, underwent prior partial or total tumor resection, MMSE ≥27).•Class V (meeting one of the following criteria: a) Age ≥50 years and underwent prior partial or total tumor resection, MMSE <27 or b) Age ≥50 years and underwent prior tumor biopsy only).

Exclusion Criteria:

  1. Prior Chemotherapy within the last 5 years.
  2. Prior RTX of the head.
  3. Receiving concurrent investigational agents or has received an investigational agent within the past 30 days prior to the first dose of cilengitide.
  4. Prior systemic antiangiogenic therapy.
  5. Placement of Gliadel® wafer at surgery.
  6. Inability to undergo Gd-MRI.
  7. Planned surgery for other diseases (e.g. dental extraction).
  8. History of recent peptic ulcer disease (endoscopically proven gastric ulcer, duodenal ulcer, or esophageal ulcer) within 6 months of enrollment.
  9. History of malignancy. Subjects with curatively treated cervical carcinoma in situ or basal cell carcinoma of the skin, or subjects who have been free of other malignancies for ³ 5 years are eligible for this study.
  10. History of coagulation disorder associated with bleeding or recurrent thrombotic events.
  11. Clinically manifest myocardial insufficiency (NYHA III, IV) or history of myocardial infarction during the past 6 months. Uncontrolled arterial hypertension.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00689221

Contacts
Contact: Andrea Schratt, Dipl., Biol. +49-6151-72 ext 2636 This e-mail address is being protected from spambots. You need JavaScript enabled to view it

Locations
United States, Massachusetts
Central US Contact Local Medical Information Office located in Recruiting
Rockland, Massachusetts, United States
Contact     888-275-7376
Germany
Central EU Contact Merck KGaA Communication Center located in Recruiting
Darmstadt, Germany
Contact     ++49 (0) 6151 72 4320
Sponsors and Collaborators
EMD Serono
European Organization for Research and Treatment of Cancer
Investigators
Study Chair: Roger Stupp, Dr. med. Centre pluridisciplinaire d'Oncologie
More Information
No publications provided

Responsible Party: Merck KGaA ( Dr. Martin Picard )
ClinicalTrials.gov Identifier: NCT00689221 History of Changes
Other Study ID Numbers: EMD 121974-011, EORTC 26071-22072
Study First Received: May 29, 2008
Last Updated: May 24, 2010
Health Authority: United States: Food and Drug Administration

Keywords provided by EMD Serono:
newly diagnosed Glioblastoma (WHO Grade IV)

Additional relevant MeSH terms:
Glioblastoma
Astrocytoma
Glioma
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Temozolomide
Dacarbazine
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Antineoplastic Agents
Therapeutic Uses
 


SAPE ERROR: Нет доступа на запись к файлу: /home/btbuddies/public_html/templates/68portal_orig/images/cache/3f9e7ffccc6995af0bc4886a484f1db1/links.db! Выставите права 777 на папку.